Teva Recasts Segment Reporting, Moves Anda Distribution to Other Activities

What Happened Teva Pharmaceutical Industries Ltd. filed a Current Report on Form 8‑K (filed Sept 3, 2026; referencing the 2025 Form 10‑K filed Feb 3, 2026) to recast historical segment information. The company moved Anda, its U.S. distribution business, out of the United States segment and into "Other Activities" effective January 1, 2026, and aligned internal financial and segment reporting (reporting units) with this change for the quarter ended March 31, 2026. Exhibit 99.1 to the 8‑K provides the updated segment disclosures in the referenced 10‑K sections.

Key Details

• Filing date: September 3, 2026; Original 10‑K filed February 3, 2026 (year ended Dec 31, 2025).
• Effective date of change in presentation: January 1, 2026; internal alignment effective for quarter ended March 31, 2026.
• Recast affects portions of the 10‑K: Item 1 (Business), Item 7 (MD&A), and Item 8 (Notes — segment reporting, revenue disaggregation, Note 19).
• The 8‑K states this is a recast of segment disclosures only — not an amendment or restatement of consolidated financial statements (balance sheet, income, cash flows remain unchanged).

Why It Matters This change shifts how revenue and operating results tied to Anda will be reported on a segment basis, which can affect how investors view Teva's U.S. segment performance versus its "Other Activities" line. Because the company did not restate consolidated financial statements, overall reported earnings and cash flows are unchanged, but segment-level comparisons to prior periods should be based on the recast disclosures in Exhibit 99.1 and read alongside the original 10‑K and subsequent 10‑Q filings for Q1 and Q2 2026.